Mark Rametta

971 total citations
19 papers, 700 citations indexed

About

Mark Rametta is a scholar working on Pathology and Forensic Medicine, Oncology and Rheumatology. According to data from OpenAlex, Mark Rametta has authored 19 papers receiving a total of 700 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pathology and Forensic Medicine, 5 papers in Oncology and 5 papers in Rheumatology. Recurrent topics in Mark Rametta's work include Multiple Sclerosis Research Studies (13 papers), Peripheral Neuropathies and Disorders (4 papers) and Rheumatoid Arthritis Research and Therapies (3 papers). Mark Rametta is often cited by papers focused on Multiple Sclerosis Research Studies (13 papers), Peripheral Neuropathies and Disorders (4 papers) and Rheumatoid Arthritis Research and Therapies (3 papers). Mark Rametta collaborates with scholars based in United States, Germany and Canada. Mark Rametta's co-authors include Anthony T. Reder, Joël Oger, Douglas S. Goodin, Gary Cutter, Volker Knappertz, Marcelo Kremenchutzky, K. Beckmann, George C. Ebers, Dawn Langdon and Ludwig Kappos and has published in prestigious journals such as PLoS ONE, Neurology and BMJ Open.

In The Last Decade

Mark Rametta

18 papers receiving 674 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Rametta United States 10 530 168 146 128 127 19 700
Rachel Farrell United Kingdom 14 359 0.7× 160 1.0× 143 1.0× 164 1.3× 136 1.1× 44 755
Stine Marit Moen Norway 15 469 0.9× 139 0.8× 88 0.6× 45 0.4× 86 0.7× 26 611
Agnès Fromont France 11 430 0.8× 85 0.5× 143 1.0× 84 0.7× 194 1.5× 30 809
M. Boggild United Kingdom 15 753 1.4× 206 1.2× 222 1.5× 105 0.8× 323 2.5× 24 1.1k
Elaine Regina Delicato de Almeida Brazil 12 238 0.4× 83 0.5× 86 0.6× 62 0.5× 66 0.5× 24 482
Anne‐Hilde Muris Netherlands 14 460 0.9× 262 1.6× 50 0.3× 53 0.4× 36 0.3× 22 674
Joseph Bruno Bidin Brooks Brazil 12 228 0.4× 76 0.5× 65 0.4× 36 0.3× 102 0.8× 36 409
Seyed-Hossein Abtahi Iran 14 282 0.5× 44 0.3× 57 0.4× 36 0.3× 109 0.9× 50 698
Bijal Mehta United States 10 188 0.4× 58 0.3× 77 0.5× 30 0.2× 81 0.6× 35 410
L. D. Jacobs Netherlands 8 270 0.5× 96 0.6× 152 1.0× 106 0.8× 97 0.8× 9 513

Countries citing papers authored by Mark Rametta

Since Specialization
Citations

This map shows the geographic impact of Mark Rametta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Rametta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Rametta more than expected).

Fields of papers citing papers by Mark Rametta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Rametta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Rametta. The network helps show where Mark Rametta may publish in the future.

Co-authorship network of co-authors of Mark Rametta

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Rametta. A scholar is included among the top collaborators of Mark Rametta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Rametta. Mark Rametta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
3.
Rametta, Mark, et al.. (2020). Sentiment of Media Coverage and Reputation of the Pharmaceutical Industry. Therapeutic Innovation & Regulatory Science. 54(1). 220–225. 1 indexed citations
4.
Rametta, Mark, et al.. (2017). Vitamin D and Multiple Sclerosis: A Comprehensive Review. Neurology and Therapy. 7(1). 59–85. 286 indexed citations
5.
6.
Ziemssen, Tjalf, et al.. (2015). Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™). Neurology and Therapy. 4(2). 125–136. 24 indexed citations
7.
Taylor, Bruce, Harold Moses, Friedemann Paul, Gustavo Cruz, & Mark Rametta. (2015). Treatment of Multiple Sclerosis – Relationship between Vitamin D and Interferon β-1b. European Neurological Review. 10(2). 124–124. 1 indexed citations
8.
Holick, Michael F., Stuart D. Cook, Gustavo Cruz, & Mark Rametta. (2015). Vitamin D Deficiency and Possible Role in Multiple Sclerosis. European Neurological Review. 10(2). 131–131. 4 indexed citations
9.
10.
Goodin, Douglas S., Michael J. Corwin, David W. Kaufman, et al.. (2014). Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States. PLoS ONE. 9(8). e105207–e105207. 30 indexed citations
11.
Reder, Anthony T., Joël Oger, Ludwig Kappos, Paul O’Connor, & Mark Rametta. (2013). Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosis. Multiple Sclerosis and Related Disorders. 3(3). 294–302. 38 indexed citations
12.
Goodin, Douglas S., George C. Ebers, Gary Cutter, et al.. (2012). Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study. BMJ Open. 2(6). e001972–e001972. 38 indexed citations
13.
Dhib‐Jalbut, Suhayl, et al.. (2012). The Combined Effect of Nursing Support and Adverse Event Mitigation on Adherence to Interferon Beta-1b Therapy in Early Multiple Sclerosis. International Journal of MS Care. 14(4). 198–208. 9 indexed citations
14.
Goodin, Douglas S., Anthony T. Reder, George C. Ebers, et al.. (2012). Survival in MS. Neurology. 78(17). 1315–1322. 178 indexed citations
15.
Dhib‐Jalbut, Suhayl, et al.. (2012). Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study. Journal of Neuroimmunology. 254(1-2). 131–140. 21 indexed citations
16.
Reder, Anthony T., Douglas S. Goodin, George C. Ebers, et al.. (2012). Clinical Outcomes and Cause of Death for Interferon Beta-1b Versus Placebo, 21 Years Following Randomization (P04.129). Neurology. 78(Meeting Abstracts 1). P04.129–P04.129.
17.
18.
Ebers, George C., Douglas S. Goodin, Anthony T. Reder, et al.. (2011). Cause of death in patients with multiple sclerosis: The 21-year long-term follow-up study. 2. 1 indexed citations
19.
Castagnetti, Carolina, et al.. (2008). Plasma levels of ACTH and cortisol in normal and critically-ill neonatal foals. Veterinary Research Communications. 32(S1). 127–129. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rachel Farrell Breakdown of academic impact, for papers by Stine Marit Moen Breakdown of academic impact, for papers by Agnès Fromont Breakdown of academic impact, for papers by M. Boggild Breakdown of academic impact, for papers by Elaine Regina Delicato de Almeida Breakdown of academic impact, for papers by Anne‐Hilde Muris Breakdown of academic impact, for papers by Joseph Bruno Bidin Brooks Breakdown of academic impact, for papers by Seyed-Hossein Abtahi Breakdown of academic impact, for papers by Bijal Mehta Breakdown of academic impact, for papers by L. D. Jacobs
Rankless by CCL
2026